Circulating TGF-β1-related biomarkers in patients with hepatocellular carcinoma and their association with HCC staging scores

Cancer Letters

Volumn 353, Issue 2, 2014, Pages 264-271

  Dituri, Francesco ^a   Serio, Gabriella ^a   Filannino, Doriana ^a   Mascolo, Antonella ^a   Sacco, Rodolfo ^b   Villa, Erica ^c   Giannelli, Gianluigi ^a  

^a Department of Biomedical Science and Human Oncology ^*  (Italy)

^b UNIVERSITY OF PISA   (Italy)

^c UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

Author keywords

AFP; Biomarkers; E cadherin; MMP 2; TGF

Indexed keywords

ALPHA FETOPROTEIN; CONNECTIVE TISSUE GROWTH FACTOR; GELATINASE A; TRANSFORMING GROWTH FACTOR BETA1; UVOMORULIN; VASCULOTROPIN; BIOLOGICAL MARKER; CADHERIN; CDH1 PROTEIN, HUMAN; CTGF PROTEIN, HUMAN; MMP2 PROTEIN, HUMAN; TGFB1 PROTEIN, HUMAN; TUMOR MARKER; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN;

AGED; ARTICLE; BCLC STAGING CLASSIFICATION; CANCER CLASSIFICATION; CANCER STAGING; CLIP SCORE; FEMALE; HUMAN; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SURVIVAL TIME; AFP; BLOOD; E-CADHERIN; KAPLAN MEIER METHOD; LIVER TUMOR; MMP-2; MORTALITY; PATHOLOGY; TGF-Β;

AFP; BIOMARKERS; E-CADHERIN; MMP-2; TGF-Β;

AGED; CADHERINS; CARCINOMA, HEPATOCELLULAR; CONNECTIVE TISSUE GROWTH FACTOR; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; LIVER NEOPLASMS; MALE; MATRIX METALLOPROTEINASE 2; NEOPLASM STAGING; TRANSFORMING GROWTH FACTOR BETA1; TUMOR MARKERS, BIOLOGICAL; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84908671704     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2014.07.029     Document Type: Article

References (29)

1. Bissell D.M. Hepatic fibrosis as wound repair: a progress report. J. Gastroenterol 1998, 33:295-302.
2. Bissell D.M. Chronic liver injury, TGF-beta, and cancer. Exp. Mol. Med 2001, 33:179-190.
3. Giannelli G., Mazzocca A., Fransvea E., Lahn M., Antonaci S. Inhibiting TGF-beta signaling in hepatocellular carcinoma. Biochim. Biophys. Acta 2011, 1815:214-223.
4. Bedossa P., Peltier E., Terris B., Franco D., Poynard T. Transforming growth factor-beta 1 (TGF-beta 1) and TGF-beta 1 receptors in normal, cirrhotic, and neoplastic human livers. Hepatology 1995, 21:760-766.
5. Shirai Y., Kawata S., Tamura S., Ito N., Tsushima H., Takaishi K., et al. Plasma transforming growth factor-beta 1 in patients with hepatocellular carcinoma. Comparison with chronic liver diseases. Cancer 1994, 73:2275-2279.
6. Giannelli G., Fransvea E., Marinosci F., Bergamini C., Colucci S., Schiraldi O., et al. Transforming growth factor-beta1 triggers hepatocellular carcinoma invasiveness via alpha3beta1 integrin. Am. J. Pathol 2002, 161:183-193.
7. Ito N., Kawata S., Tamura S., Shirai Y., Kiso S., Tsushima H., et al. Positive correlation of plasma transforming growth factor-beta 1 levels with tumor vascularity in hepatocellular carcinoma. Cancer Lett 1995, 89:45-48.
8. Hoshida Y., Nijman S.M., Kobayashi M., Chan J.A., Brunet J.P., Chiang D.Y., et al. Integrative transcriptome analysis reveals common molecular subclasses of human hepatocellular carcinoma. Cancer Res 2009, 69:7385-7392.
9. Giannelli G.F.S., Santoro A., Kelley R.K., Merle P., Gane E., Douillard J.Y.W.D., et al. Evaluation of LY2157299 monohydrate (LY), a TGF-b receptor I kinase inhibitor, in patients with advanced hepatocellular carcinoma: phase 2 study results of safety, efficacy and PK/PD. J. Hepatol 2014, 60:S45-S66.
10. Dienstmann R., Rodon J., Tabernero J. Biomarker-driven patient selection for early clinical trials. Curr. Opin. Oncol 2013, 25:305-312.
11. Sjoblom T., Jones S., Wood L.D., Parsons D.W., Lin J., Barber T.D., et al. The consensus coding sequences of human breast and colorectal cancers. Science 2006, 314:268-274.
12. Pickup M., Novitskiy S., Moses H.L. The roles of TGFbeta in the tumour microenvironment. Nat. Rev. Cancer 2013, 13:788-799.
13. Llovet J.M., Bru C., Bruix J. Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin. Liver Dis 1999, 19:329-338.
14. Duvoux C., Roudot-Thoraval F., Decaens T., Pessione F., Badran H., Piardi T., et al. Liver transplantation for hepatocellular carcinoma: a model including alpha-fetoprotein improves the performance of Milan criteria. Gastroenterology 2012, 143:986-994 e983. quiz e914-985.
15. Johnson P.J., Qin S., Park J.W., Poon R.T., Raoul J.L., Philip P.A., et al. Brivanib versus sorafenib as first-line therapy in patients with unresectable, advanced hepatocellular carcinoma: results from the randomized phase III BRISK-FL study. J. Clin. Oncol 2013, 31:3517-3524.
16. Lee Y.K., Kim S.U., Kim Do Y., Ahn S.H., Lee K.H., Lee Do Y., et al. Prognostic value of alpha-fetoprotein and des-gamma-carboxy prothrombin responses in patients with hepatocellular carcinoma treated with transarterial chemoembolization. BMC Cancer 2013, 13:5.
17. Poon R.T., Lau C.P., Cheung S.T., Yu W.C., Fan S.T. Quantitative correlation of serum levels and tumor expression of vascular endothelial growth factor in patients with hepatocellular carcinoma. Cancer Res 2003, 63:3121-3126.
18. Okumoto K., Hattori E., Tamura K., Kiso S., Watanabe H., Saito K., et al. Possible contribution of circulating transforming growth factor-beta1 to immunity and prognosis in unresectable hepatocellular carcinoma. Liver Int 2004, 24:21-28.
19. Bergamini C., Sgarra C., Trerotoli P., Lupo L., Azzariti A., Antonaci S., et al. Laminin-5 stimulates hepatocellular carcinoma growth through a different function of alpha6beta4 and alpha3beta1 integrins. Hepatology 2007, 46:1801-1809.
20. Giannelli G., Antonaci S. Biological and clinical relevance of Laminin-5 in cancer. Clin. Exp. Metastasis 2001, 18:439-443.
21. Inayoshi J., Ichida T., Sugitani S., Tsuboi Y., Genda T., Honma N., et al. Gross appearance of hepatocellular carcinoma reflects E-cadherin expression and risk of early recurrence after surgical treatment. J. Gastroenterol. Hepatol 2003, 18:673-677.
22. Dituri F., Mazzocca A., Peidro F.J., Papappicco P., Fabregat I., De Santis F., et al. Differential Inhibition of the TGF-beta Signaling Pathway in HCC Cells Using the Small Molecule Inhibitor LY2157299 and the D10 Monoclonal Antibody against TGF-beta Receptor Type II. PLoS ONE 2013, 8:e67109.
23. Calvisi D.F., Ladu S., Conner E.A., Factor V.M., Thorgeirsson S.S. Disregulation of E-cadherin in transgenic mouse models of liver cancer. Lab. Invest 2004, 84:1137-1147.
24. Fransvea E., Mazzocca A., Santamato A., Azzariti A., Antonaci S., Giannelli G. Kinase activation profile associated with TGF-beta-dependent migration of HCC cells: a preclinical study. Cancer Chemother. Pharmacol 2011, 68:79-86.
25. Herbst R.S. Dose-comparative monotherapy trials of ZD1839 in previously treated non-small cell lung cancer patients. Semin. Oncol 2003, 30:30-38.
26. Kris M.G., Natale R.B., Herbst R.S., Lynch T.J., Prager D., Belani C.P., et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA 2003, 290:2149-2158.
27. Thiery J.P. Epithelial-mesenchymal transitions in tumour progression. Nat. Rev. Cancer 2002, 2:442-454.
28. Villa E.C.R., Turola E., Lei B., Colopi S., Ballestri S., Berselli S., et al. 7th ILCA Annual Conference 2013, Washington.
29. Hartland S.N., Murphy F., Aucott R.L., Abergel A., Zhou X., Waung J., et al. Active matrix metalloproteinase-2 promotes apoptosis of hepatic stellate cells via the cleavage of cellular N-cadherin. Liver Int 2009, 29:966-978.